Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA) has granted inducement awards to three new employees under its 2024 Inducement Plan. The grants consist of time-based restricted stock units (RSUs) for 23,155 shares of common stock, which will vest in three equal installments on January 1 of 2026, 2027, and 2028. The vesting is contingent upon continued employment with Intellia.
These awards were granted outside of Intellia's stockholder-approved equity incentive plans through the 2024 Inducement Plan, which was adopted by the board in June 2024. The compensation committee approved these grants as material inducement for employment in compliance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha concesso premi di incentivazione a tre nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2024. I premi consistono in unità di azioni restrittive (RSU) basate sul tempo per 23.155 azioni di azioni ordinarie, che verranno acquisite in tre rate uguali il 1° gennaio del 2026, 2027 e 2028. L'acquisizione è subordinata all'impiego continuato con Intellia.
Questi premi sono stati concessi al di fuori dei piani di incentivazione approvati dagli azionisti di Intellia attraverso il Piano di Incentivazione 2024, adottato dal consiglio a giugno 2024. Il comitato di compensazione ha approvato questi premi come indennità materiale per l'impiego in conformità con Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha otorgado premios de incentivo a tres nuevos empleados bajo su Plan de Incentivo 2024. Los premios consisten en unidades de acciones restringidas (RSUs) basadas en el tiempo para 23,155 acciones de acciones ordinarias, que se consolidarán en tres partes iguales el 1 de enero de 2026, 2027 y 2028. La consolidación está sujeta a la continuación del empleo con Intellia.
Estos premios se otorgaron fuera de los planes de incentivos de acciones aprobados por los accionistas de Intellia a través del Plan de Incentivo 2024, que fue adoptado por la junta en junio de 2024. El comité de compensación aprobó estos premios como incentivo material para el empleo en cumplimiento de Nasdaq Listing Rule 5635(c)(4).
인텔리아 테라퓨틱스(NASDAQ:NTLA)는 2024 유인 계획에 따라 세 명의 신입 직원에게 유인 보상을 지급했습니다. 이 보상은 23,155주의 보통주에 대한 시간 기반 제한 주식 단위(RSU)로 구성되며, 2026년, 2027년, 2028년 1월 1일에 세 번 동일한 비율로 취득됩니다. 취득은 인텔리아와 계속 고용되는 조건에 따라 이루어집니다.
이 보상은 2024 유인 계획을 통해 인텔리아의 주주가 승인한 주식 인센티브 계획 외부에서 지급되었습니다. 이 계획은 2024년 6월 이사회에서 채택되었습니다. 보상 위원회는 납삭 상장 규정 5635(c)(4)를 준수하여 고용에 대한 물질적 유인으로 이 보상을 승인했습니다.
Intellia Therapeutics (NASDAQ:NTLA) a accordé des récompenses d'incitation à trois nouveaux employés dans le cadre de son Plan d'Incitation 2024. Les récompenses se composent d'unités d'actions restreintes (RSU) en fonction du temps pour 23 155 actions ordinaires, qui acquériront leurs droits en trois versements égaux le 1er janvier 2026, 2027 et 2028. L'acquisition des droits est conditionnée à la poursuite de l'emploi chez Intellia.
Ces récompenses ont été octroyées en dehors des plans d'incitation en actions approuvés par les actionnaires d'Intellia par le biais du Plan d'Incitation 2024, qui a été adopté par le conseil d'administration en juin 2024. Le comité de rémunération a approuvé ces récompenses comme une incitation matérielle à l'emploi conformément à la règle d'inscription Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) hat drei neuen Mitarbeitern Verleihungen im Rahmen seines Anreizplans 2024 gewährt. Die Verleihungen bestehen aus zeitbasierten eingeschränkten Aktieneinheiten (RSUs) für 23.155 Aktien des Stammkapitals, die in drei gleichen Raten am 1. Januar 2026, 2027 und 2028 fällig werden. Die Vesting-Bedingungen hängen von der fortgesetzten Anstellung bei Intellia ab.
Diese Belohnungen wurden außerhalb der von den Aktionären genehmigten Aktienanreizpläne von Intellia im Rahmen des Anreizplans 2024 gewährt, der im Juni 2024 vom Vorstand beschlossen wurde. Der Vergütungsausschuss genehmigte diese Verleihungen als wesentlichen Anreiz für die Beschäftigung in Übereinstimmung mit Nasdaq Listing Rule 5635(c)(4).
- Company demonstrates ability to attract new talent with equity compensation
- Structured vesting schedule over three years promotes employee retention
- Potential dilution of existing shareholders through new stock issuance
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on January 1, 2025, it awarded inducement grants to three new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for 23,155 shares of Intellia’s common stock, with one-third of such RSUs vesting on January 1, 2026, 2027, and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. The awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
Brittany.Chaves@intelliatx.com
FAQ
How many shares were granted in Intellia's (NTLA) January 2025 inducement awards?
What is the vesting schedule for NTLA's January 2025 inducement grants?
When was Intellia's (NTLA) 2024 Inducement Plan adopted?
Under which Nasdaq rule were NTLA's January 2025 inducement grants approved?
